303 related articles for article (PubMed ID: 26939702)
21. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
22. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
23. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Baratta MG; Schinzel AC; Zwang Y; Bandopadhayay P; Bowman-Colin C; Kutt J; Curtis J; Piao H; Wong LC; Kung AL; Beroukhim R; Bradner JE; Drapkin R; Hahn WC; Liu JF; Livingston DM
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):232-7. PubMed ID: 25535366
[TBL] [Abstract][Full Text] [Related]
24. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
25. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
Kumar K; Raza SS; Knab LM; Chow CR; Kwok B; Bentrem DJ; Popovic R; Ebine K; Licht JD; Munshi HG
Sci Rep; 2015 Mar; 5():9489. PubMed ID: 25807524
[TBL] [Abstract][Full Text] [Related]
26. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines.
Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB
Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941
[TBL] [Abstract][Full Text] [Related]
27. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
[TBL] [Abstract][Full Text] [Related]
28. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
29. Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.
Chen Y; Xie H; Zou Y; Lai X; Ma L; Liu Y; Li J
Mol Biosyst; 2017 Jul; 13(8):1597-1607. PubMed ID: 28671703
[TBL] [Abstract][Full Text] [Related]
30. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer.
Gao X; Wu X; Zhang X; Hua W; Zhang Y; Maimaiti Y; Gao Z; Zhang Y
Biochem Biophys Res Commun; 2016 Jan; 469(3):679-85. PubMed ID: 26707881
[TBL] [Abstract][Full Text] [Related]
32. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
33. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.
Segura MF; Fontanals-Cirera B; Gaziel-Sovran A; Guijarro MV; Hanniford D; Zhang G; González-Gomez P; Morante M; Jubierre L; Zhang W; Darvishian F; Ohlmeyer M; Osman I; Zhou MM; Hernando E
Cancer Res; 2013 Oct; 73(20):6264-76. PubMed ID: 23950209
[TBL] [Abstract][Full Text] [Related]
34. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
35. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.
Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA
Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072
[TBL] [Abstract][Full Text] [Related]
36. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
[TBL] [Abstract][Full Text] [Related]
37. A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
Mqoco T; Stander A; Engelbrecht AM; Joubert AM
Biomed Res Int; 2019; 2019():1850462. PubMed ID: 31886177
[TBL] [Abstract][Full Text] [Related]
38. Transcriptionally elevation of miR-494 by new ChlA-F compound via a HuR/JunB axis inhibits human bladder cancer cell invasion.
Tian Z; Luo Y; Zhu J; Hua X; Xu J; Huang C; Jin H; Huang H; Huang C
Biochim Biophys Acta Gene Regul Mech; 2019 Aug; 1862(8):822-833. PubMed ID: 31167152
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.
Ishi Y; Zhang Y; Zhang A; Sasaki T; Piunti A; Suri A; Watanabe J; Abe K; He X; Katagi H; Bhalla P; Natsumeda M; Zou L; Shilatifard A; Hashizume R
Mol Cancer Ther; 2022 May; 21(5):715-726. PubMed ID: 35247919
[TBL] [Abstract][Full Text] [Related]
40. Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation.
Kong IY; Rimes JS; Light A; Todorovski I; Jones S; Morand E; Knight DA; Bergman YE; Hogg SJ; Falk H; Monahan BJ; Stupple PA; Street IP; Heinzel S; Bouillet P; Johnstone RW; Hodgkin PD; Vervoort SJ; Hawkins ED
Cell Rep; 2020 Oct; 33(3):108290. PubMed ID: 33086063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]